Drägerwerk stock benefits from stronger H1 2026 profitability

Drägerwerk stock is drawing attention as the medical and safety technology group reports higher net sales and a tripling of EBIT in the first half of 2026, while reiterating guidance for moderate full-year growth.

Drägerwerk AG & Co. KGaA (DE0005550636) reported a clear improvement in profitability in the first half of 2026, with EBIT rising to around EUR 64 million and the EBIT margin increasing to 4.0 percent, supported by higher net sales and an improved gross margin in both divisions as outlined in a transcript dated August 26, 2026. The company also indicated that order intake in the first six months of 2026 was slightly above the already high prior-year level, underlining continued demand for its medical and safety technology solutions.

H1 2026 results show higher sales and margins

According to a detailed half-year 2026 presentation, Drägerwerk generated net sales of around EUR 1.6 billion in the first six months of 2026, an increase of more than EUR 90 million compared with the same period a year earlier, while order intake reached around EUR 1.75 billion, slightly above the strong prior-year reference. The H1 2026 transcript notes that the company's gross margin improved by 1.7 percentage points to 46.5 percent in this period, reflecting both pricing and mix effects across its core markets.

In terms of profitability, Drägerwerk's EBIT in the first half of 2026 increased from around EUR 20 million in the prior-year period to around EUR 64 million, lifting the EBIT margin from 1.3 percent to 4.0 percent and thus adding 2.7 percentage points. The same document highlights that in the second quarter of 2026 alone, EBIT more than doubled from around EUR 20 million to around EUR 46 million, with the quarterly EBIT margin rising by 2.6 percentage points to 5.4 percent, helped by stronger net sales, a higher gross margin and a one-off customs refund of EUR 7.8 million recognized in cost of goods sold.

Cash flow and value-added metrics improve

The half-year 2026 update also indicates that Drägerwerk's free cash flow improved to around EUR 16 million in the first six months of 2026, supported by the better earnings performance, after a weaker contribution in the previous year. In addition, the company reported that its rolling 12-month DVA, a value-added metric, increased from around EUR 17 million to around EUR 129 million over the same period, underscoring the scale of the turnaround in profitability and capital efficiency compared with the earlier baseline.

Management continues to guide for net sales growth between 2 percent and 6 percent for the full year 2026 on a currency-adjusted basis, according to the H1 2026 communication. For investors, this combination of higher margins, improved free cash flow and an unchanged moderate growth outlook suggests that Drägerwerk is working to consolidate the gains achieved in the first half while staying focused on disciplined cost control and operational efficiency.

Medical and safety technology as a growth driver

Drägerwerk's business is built around medical technology such as ventilators, anesthesia workstations and patient monitoring systems, as well as safety technology including gas detection and respiratory protection equipment for industrial and emergency applications. The company highlighted in its half-year discussion that both major divisions contributed to the improvement in gross margin in the first half of 2026, indicating that value-added solutions in critical care and safety are helping to support pricing and profitability.

With net sales in the first half of 2026 rising by more than EUR 90 million compared with the prior year and EBIT more than tripling to around EUR 64 million, the operational leverage in the business becomes clear. If Drägerwerk succeeds in maintaining an EBIT margin in the mid-single-digit range or higher while delivering net sales growth within the 2 percent to 6 percent corridor, the company could continue to translate incremental revenue into a proportionally larger increase in operating profit.

Representative product: hospital ventilation solutions

One representative product category for Drägerwerk is its range of hospital ventilation systems, which are designed to support patients with respiratory insufficiency in intensive care and operating room environments. These systems typically integrate advanced monitoring features, configurable ventilation modes and interfaces that enable clinicians to tailor therapy to the patient's needs while maintaining workflow efficiency in complex care settings.

Drägerwerk stock and valuation context

Drägerwerk stock is traded on its home market exchange, providing investors with exposure to a company that has reported net sales of around EUR 1.6 billion and an EBIT margin of 4.0 percent in the first half of 2026, as documented in the H1 2026 transcript. Against this backdrop, the company's guidance for currency-adjusted net sales growth between 2 percent and 6 percent in 2026 and the significant increase in rolling 12-month DVA from around EUR 17 million to around EUR 129 million offer a quantitative framework for assessing the share's valuation and future earnings power.

Fact box

Company: Drägerwerk AG & Co. KGaA
ISIN: DE0005550636
Ticker: not specified
Exchange: home exchange listing
Sector / Industry: medical technology and safety equipment